AIMS/INTRODUCTION Dipeptidyl peptidase-4 inhibitors (DPP-4i) are a common first-line treatment for type 2 diabetes in Japan. However, little is known about patients' medication adherence, persistence and discontinuation in this setting. MATERIALS AND METHODS This was a retrospective cohort study of new DPP-4i users in a Japanese claims database. Adult patients (age 18-65 years) with type 2 di...

Dipeptidyl-4 (DPP-4) inhibitors are oral antidiabetic agents recently introduced to Malaysia. Thus, limited data is available on their utilization patterns and factors associated with their use. This study aims to analyse the utilization patterns of DPP-4 inhibitors, factors that influenced the choice of agent, and the rationale for treatment with DPP-4 inhibitors in patients with type 2 diabet...

oxidation of different types of 1,4-dihydropyridines with diphenylpicrylhydrazyl (dpp) and benzoyl peroxide (bz2o2) as free radical oxidizing agents to pyridine derivatives is reported and a mechanism for this oxidation is also proposed.

Inhibitors of dipeptidyl peptidase IV (DPP-4; an ectoenzyme also called CD26) represent a novel, effective, and useful class of antidiabetic drugs for treatment of type 2 diabetes. Drugs in this class (eg, sitagliptin [Januvia], saxagliptin [Onglyza], and vildagliptin [Galvus]) afford significant and sustained reductions in hemoglobin A1c with a low risk of hypoglycemia and little effect on bod...

Objective Evaluations of lifestyle modification interventions (LMIs), modeled after the DPP, have repeatedly shown a dose-response relationship between session attendance and weight loss. Despite this, not all participants “average” loss experiences. Nearly one-third LMI experienced unexpected, paradoxical outcomes (i.e., high with little loss, low clinically significant loss). Paradoxical weig...

BI 1356 [proposed trade name ONDERO; (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] is a novel dipeptidyl peptidase (DPP)-4 inhibitor under clinical development for the treatment of type 2 diabetes. In this study, we investigated the potency, selectivity, mechanism, and duration of action of BI 1356 in vitro and in vivo and ...

Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentrations of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide...

Coronaviruses (CoVs) are a group of viruses that induce infection in the respiratory and other systems in the human body. There are two coronaviruses that transmitted from animals to humans including severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) (1). The novel coronavirus that appeared at first in Wuhan, China, in December 2019 was named as severe acut...